A recent study showed that, in patients with HER2-positive breast cancer with trastuzumab emtansine-resistant disease, 59.5% of patients achieved an objective response and a progression-free survival of 22 months, with most of responses being durable [500]. Here, ERBB2 is linked to breast carcinoma.